The Ca²⁺/Calmodulin-dependent Calcineurin/NFAT Signaling Pathway in the Pathogenesis of Insulin Resistance in Skeletal Muscle

 

 Buy Article Permissions and Reprints

Abstract

Skeletal muscle is the tissue directly involved in insulin-stimulated glucose uptake. Glucose is the primary energy substrate for contracting muscles, and proper metabolism of glucose is essential for health. Contractile activity and the associated Ca²⁺signaling regulate functional capacity and muscle mass. A high concentration of Ca²⁺and the presence of calmodulin (CaM) leads to the activation of calcineurin (CaN), a protein with serine-threonine phosphatase activity. The signaling pathway linked with CaN and transcription factors like the nuclear factor of activated T cells (NFAT) is essential for skeletal muscle development and reprogramming of fast-twitch to slow-twitch fibers. CaN activation may promote metabolic adaptations in muscle cells, resulting in better insulin-stimulated glucose transport. The molecular mechanisms underlying the altered insulin response remain unclear. The role of the CaN/NFAT pathway in regulating skeletal muscle hypertrophy is better described than its involvement in the pathogenesis of insulin resistance. Thus, there are opportunities for future research in that field. This review presents the role of CaN/NFAT signaling and suggests the relationship with insulin-resistant muscles.

Publication History

Received: 11 May 2023
Received: 03 August 2023

Accepted: 04 September 2023

Article published online:
24 October 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Ryder JW, Bassel-Duby R, Olson EN. et al. Skeletal muscle reprogramming by activation of calcineurin improves insulin action on metabolic pathways. J Biol Chem 2003; 278: 44298-44304
  CrossrefPubMedGoogle Scholar
• 2 Jiang LQ, Garcia-Roves PM, de Castro Barbosa T. et al. Constitutively active calcineurin in skeletal muscle increases endurance performance and mitochondrial respiratory capacity. Am J Physiol Endocrinol Metab 2010; 298: E8-E16
  PubMedGoogle Scholar
• 3 Braun T, Gautel M. Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. Nat Rev Mol Cell Biol 2011; 12: 349-361
  CrossrefPubMedGoogle Scholar
• 4 Merz KE, Thurmond DC. Role of skeletal muscle in insulin resistance and glucose uptake. Compr Physiology 2020; 10: 785-809
  CrossrefPubMedGoogle Scholar
• 5 Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. Physiol Rev 2013; 93: 993-1017
  CrossrefPubMedGoogle Scholar
• 6 Attwaters M, Hughes SM. Cellular and molecular pathways controlling muscle size in response to exercise. FEBS J 2022; 289: 1428-1456
  CrossrefPubMedGoogle Scholar
• 7 Barazzoni R, Gortan Cappellari G, Ragni M. et al. Insulin resistance in obesity: An overview of fundamental alterations. Eat Weight Disord 2018; 23: 149-157
  CrossrefPubMedGoogle Scholar
• 8 Tallis J, James RS, Seebacher F. The effects of obesity on skeletal muscle contractile function. J Exp Biol 2018; 221: jeb163840
  CrossrefPubMedGoogle Scholar
• 9 Bryant NJ, Gould GW. Insulin stimulated GLUT4 translocation-Size is not everything!. Curr Opin Cell Biol 2020; 65: 28-34
  CrossrefPubMedGoogle Scholar
• 10 Chakkera HA, Kudva Y, Kaplan B. Calcineurin inhibitors: Pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus. Clin Pharmacol Ther 2017; 101: 114-120
  CrossrefPubMedGoogle Scholar
• 11 Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev 2018; 98: 2133-2223
  CrossrefPubMedGoogle Scholar
• 12 Deshmukh AS. Insulin-stimulated glucose uptake in healthy and insulin-resistant skeletal muscle. Horm Mol Biol Clin Investig 2016; 26: 13-24
  CrossrefPubMedGoogle Scholar
• 13 Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012; 33: 981-1030
  CrossrefPubMedGoogle Scholar
• 14 Ormazabal V, Nair S, Elfeky O. et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 2018; 17: 1-14
  CrossrefPubMedGoogle Scholar
• 15 De la Monte SM. Insulin resistance and neurodegeneration: Progress towards the development of new therapeutics for Alzheimer’s disease. Drugs 2017; 77: 47-65
  CrossrefPubMedGoogle Scholar
• 16 Djiogue S, Kamdje AHN, Vecchio L. et al. Insulin resistance and cancer: The role of insulin and IGFs. Endocr Relat Cancer 2013; 20: R1-R17
  CrossrefPubMedGoogle Scholar
• 17 Hu J, Shi D, Ding M. et al. Calmodulin-dependent signaling pathways are activated and mediate the acute inflammatory response of injured skeletal muscle. J Physiol 2019; 597: 5161-5177
  CrossrefPubMedGoogle Scholar
• 18 Thiel G, Schmidt T, Rössler OG. Ca²⁺microdomains, calcineurin and the regulation of gene transcription. Cells 2021; 10: 875
  CrossrefPubMedGoogle Scholar
• 19 Olson EN, Williams RS. Remodeling muscles with calcineurin. Bioessays 2000; 22: 510-519
  CrossrefPubMedGoogle Scholar
• 20 Rusnak F, Mertz P. Calcineurin: Form and function. Physiol Rev 2000; 80: 1483-1521
  CrossrefPubMedGoogle Scholar
• 21 Ye Q, Feng Y, Yin Y. et al. Structural basis of calcineurin activation by calmodulin. Cell signal 2013; 25: 2661-2667
  CrossrefPubMedGoogle Scholar
• 22 Al-Shanti N, Stewart CE. Ca2+/calmodulin-dependent transcriptional pathways: Potential mediators of skeletal muscle growth and development. Biol Rev 2009; 84: 637-652
  CrossrefPubMedGoogle Scholar
• 23 Creamer TP. Calcineurin. Cell Commun Signal 2020; 18: 1-12
  CrossrefPubMedGoogle Scholar
• 24 Ulengin-Talkish I, Cyert MS. A cellular atlas of calcineurin signaling. Biochim Biophys Acta – Mol Cell Res 2023; 1870: 119366
  CrossrefPubMedGoogle Scholar
• 25 Hudson MB, Price SR. Calcineurin: A poorly understood regulator of muscle mass. Int J Biochem Cell Biol 2013; 45: 2173-2178
  CrossrefPubMedGoogle Scholar
• 26 Schulz RA, Yutzey KE. Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development. Dev Biol 2004; 266: 1-16
  CrossrefPubMedGoogle Scholar
• 27 Villota-Narvaez Y, Ramírez-Martínez A, Garzón-Alvarado D. et al. A dynamical model for the calcineurin-NFATc signaling pathway and muscle fiber shifting. Proc Appl Math Mech 2021; 20: e202000274
  CrossrefPubMedGoogle Scholar
• 28 Michel RN, Chin ER, Chakkalakal JV. et al. Ca2+/calmodulin-based signalling in the regulation of the muscle fibre phenotype and its therapeutic potential via modulation of utrophin A and myostatin expression. Appl Physiol Nutr Metab 2007; 32: 921-929
  CrossrefPubMedGoogle Scholar
• 29 Kar P, Mirams GR, Christian HC. et al. Control of NFAT isoform activation and NFAT-dependent gene expression through two coincident and spatially segregated intracellular Ca2+signals. Mol Cell 2016; 64: 746-759
  CrossrefPubMedGoogle Scholar
• 30 O’Neill BT, Lauritzen HP, Hirshman MF. et al. Differential role of insulin/IGF-1 receptor signaling in muscle growth and glucose homeostasis. Cell Rep 2015; 11: 1220-1235
  CrossrefPubMedGoogle Scholar
• 31 Roberts-Wilson TK, Reddy RN, Bailey JL. et al. Calcineurin signaling and PGC-1α expression are suppressed during muscle atrophy due to diabetes. Biochim Biophys Acta - Mol Cell Res 2010; 1803: 960-967
  CrossrefPubMedGoogle Scholar
• 32 Wang CH, Wei YH. Role of mitochondrial dysfunction and dysregulation of Ca2+homeostasis in the pathophysiology of insulin resistance and type 2 diabetes. J Biomed Sci 2017; 24: 1-11
  PubMedGoogle Scholar
• 33 Ryder JW, Long YC, Nilsson E. et al. Effects of calcineurin activation on insulin-, AICAR- and contraction-induced glucose transport in skeletal muscle. J Physiol 2005; 567: 379-386
  CrossrefPubMedGoogle Scholar
• 34 Navarro-Marquez M, Torrealba N, Troncoso R. et al. Herpud1 impacts insulin-dependent glucose uptake in skeletal muscle cells by controlling the Ca2+-calcineurin-Akt axis. Biochim Biophys Acta – Mol Basis Dis 2018; 1864: 1653-1662
  CrossrefPubMedGoogle Scholar
• 35 Rodriguez-Rodriguez AE, Porrini E, Torres A. Beta-cell dysfunction induced by tacrolimus: A way to explain type 2 diabetes?. Int J Mol Sci 2021; 22: 10311
  CrossrefPubMedGoogle Scholar
• 36 Alfieri CM, Evans-Anderson HJ, Yutzey KE. Developmental regulation of the mouse IGF-I exon 1 promoter region by calcineurin activation of NFAT in skeletal muscle. Am J Physiol Cell Physiol 2007; 292: C1887-C1894
  CrossrefPubMedGoogle Scholar
• 37 Calabria E, Ciciliot S, Moretti I. et al. NFAT isoforms control activity-dependent muscle fiber type specification. Proc Natl Acad Sci 2009; 106: 13335-13340
  CrossrefPubMedGoogle Scholar
• 38 Jiang LQ, Garcia-Roves PM, de Castro Barbosa T. et al. Constitutively active calcineurin in skeletal muscle increases endurance performance and mitochondrial respiratory capacity. Am J Physiol – Endocrinol Metab 2010; 298: E8-E16
  CrossrefPubMedGoogle Scholar
• 39 Calderón-DuPont D, Torre-Villalvazo I, Díaz-Villaseñor A. Is insulin resistance tissue-dependent and substrate-specific? The role of white adipose tissue and skeletal muscle. Biochimie 2022; 204: 48-68
  CrossrefPubMedGoogle Scholar
• 40 Madsen K, Reddy RN, Price SR. et al. Nutritional intervention restores muscle but not kidney phenotypes in adult calcineurin Aα null mice. PloS ONE 2013; 8: e62503
  CrossrefPubMedGoogle Scholar
• 41 Yang TT, Suk HY, Yang X. et al. Role of transcription factor NFAT in glucose and insulin homeostasis. Mol Cell Biol 2006; 26: 7372-7387
  CrossrefPubMedGoogle Scholar
• 42 Ni YG, Wang N, Cao DJ. et al. FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci 2007; 104: 20517-20522
  CrossrefPubMedGoogle Scholar
• 43 Stefanowicz M, Nikołajuk A, Matulewicz N. et al. Skeletal muscle RUNX1 is related to insulin sensitivity through its effect on myogenic potential. Eur J Endocrinol 2022; 187: 143-157
  CrossrefPubMedGoogle Scholar
• 44 Chakkera HA, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation 2013; 95: 647-652
  CrossrefPubMedGoogle Scholar
• 45 Chan B, Greenan G, McKeon F. et al. Identification of a peptide fragment of DSCR1 that competitively inhibits calcineurin activity in vitro and in vivo. Proc Natl Acad Sci USA 2005; 102: 13075-13080
  CrossrefPubMedGoogle Scholar
• 46 Pereira MJ, Palming J, Rizell M. et al. Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: Increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents. J Clin Endocrinol Metab 2014; 99: E1885-E1894
  CrossrefPubMedGoogle Scholar
• 47 Sakuma K, Yamaguchi A. The functional role of calcineurin in hypertrophy, regeneration, and disorders of skeletal muscle. J Biomed Biotechnol 2010; 2010: 721219
  CrossrefPubMedGoogle Scholar